Drug-sensing hydrogels for the inducible release of biopharmaceuticals
Source abstract
Abstract
Drug-dependent dissociation or association of cellular receptors represents a potent pharmacologic mode of action for regulating cell fate and function. Transferring the knowledge of pharmacologically triggered protein-protein interactions to materials science will enable novel design concepts for stimuli-sensing smart hydrogels. Here, we show the design and validation of an antibiotic-sensing hydrogel for the trigger-inducible release of human vascular endothelial growth factor. Genetically engineered bacterial gyrase subunit B (GyrB) (ref. 4) coupled to polyacrylamide was dimerized by the addition of the aminocoumarin antibiotic coumermycin, resulting in hydrogel formation. Addition of increasing concentrations of clinically validated novobiocin (Albamycin) dissociated the GyrB subunits, thereby resulting in dissociation of the hydrogel and dose- and time-dependent liberation of the entrapped protein pharmaceutical VEGF(121) for triggering proliferation of human umbilical vein endothelial cells. Pharmacologically controlled hydrogels have the potential to fulfil the promises of stimuli-sensing materials as smart devices for spatiotemporally controlled delivery of drugs within the patient.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · 3D Printing in Biomedical Research · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (24)
Show source-provided references
1. Farrar, M. A., Alberol, I. & Perlmutter, R. M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 383, 178–181 (1996).10.1038/383178a0 ↗
2. Hacker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204–207 (2006).10.1038/nature04369 ↗
3. Ehrbar, M. et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 94, 1124–1132 (2004).10.1161/01.RES.0000126411.29641.08 ↗
4. Denhardt, D. T. DNA gyrase and DNA unwinding. Nature 280, 196–198 (1979).10.1038/280196a0 ↗
5. Ehrick, J. D. et al. Genetically engineered protein in hydrogels tailors stimuli-responsive characteristics. Nature Mater. 4, 298–302 (2005).10.1038/nmat1352 ↗
6. Lendlein, A., Jiang, H., Junger, O. & Langer, R. Light-induced shape-memory polymers. Nature 434, 879–882 (2005).10.1038/nature03496 ↗
7. Miyata, T., Asami, N. & Uragami, T. A reversibly antigen-responsive hydrogel. Nature 399, 766–769 (1999).10.1038/21619 ↗
8. Wang, C., Stewart, R. J. & Kopecek, J. Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature 397, 417–420 (1999).10.1038/17092 ↗
9. Thornton, P. D., McConnell, G. & Ulijn, R. V. Enzyme responsive polymer hydrogel beads. Chem. Commun. (Camb) 47, 5913–5915 (2005).10.1039/b511005j ↗
10. Lutolf, M. P. et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nature Biotechnol. 21, 513–518 (2003).10.1038/nbt818 ↗
11. Um, S. H. et al. Enzyme-catalysed assembly of DNA hydrogel. Nature Mater. 5, 797–801 (2006).10.1038/nmat1741 ↗
12. Toledano, S., Williams, R. J., Jayawarna, V. & Ulijn, R. V. Enzyme-triggered self-assembly of peptide hydrogels via reversed hydrolysis. J. Am. Chem. Soc. 128, 1070–1071 (2006).10.1021/ja056549l ↗
13. Murakami, Y. & Maeda, M. DNA-responsive hydrogels that can shrink or swell. Biomacromolecules 6, 2927–2929 (2005).10.1021/bm0504330 ↗
14. Kopecek, J. Smart and genetically engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci. 20, 1–16 (2003).10.1016/S0928-0987(03)00164-7 ↗
15. Lutolf, M. P. & Hubbell, J. A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nature Biotechnol. 23, 47–55 (2005).10.1038/nbt1055 ↗
16. Beebe, D. J. et al. Functional hydrogel structures for autonomous flow control inside microfluidic channels. Nature 404, 588–590 (2000).10.1038/35007047 ↗
17. Clardy, J., Fischbach, M. A. & Walsh, C. T. New antibiotics from bacterial natural products. Nature Biotechnol. 24, 1541–1550 (2006).10.1038/nbt1266 ↗
18. Gormley, N. A., Orphanides, G., Meyer, A., Cullis, P. M. & Maxwell, A. The interaction of coumarin antibiotics with fragments of DNA gyrase B protein. Biochemistry 35, 5083–5092 (1996).10.1021/bi952888n ↗
19. Winter, H. H. & Chambon, F. Analysis of linear viscoelasticity of a crosslinking polymer at the gel point. J. Rheol. 30, 367–382 (1986).10.1122/1.549853 ↗
20. Lutolf, M. P. & Hubbell, J. A. Synthesis and physicochemical characterization of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type addition. Biomacromolecules 4, 713–722 (2003).10.1021/bm025744e ↗
21. Ehrbar, M., Metters, A., Zammaretti, P., Hubbell, J. A. & Zisch, A. H. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J. Control Release 101, 93–109 (2005).10.1016/j.jconrel.2004.07.018 ↗
22. Eder, J. P., Wheeler, C. A., Teicher, B. A. & Schnipper, L. E. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 51, 510–513 (1991).
23. Murren, J. R. et al. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies. Cancer J. 6, 256–265 (2000).
24. Aggarwal, S. What’s fueling the biotech engine? Nature Biotechnol. 25, 1097–1104 (2007).10.1038/nbt1007-1097 ↗